Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | MCOLN3 | Q8TDD5 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | MMP2 | P08253 | 1/20 | 0.43 |
| ▸ | ANPEP | P15144 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.41 |
| ▸ | FKBP1A | P62942 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4527207 | 1.00 | POLB (0.53) | POLBMCOLN3L3MBTL1KMT2AALDH1A1 | |
| SCHEMBL13934763 | 0.86 | POLB (0.44) | POLBMCOLN3L3MBTL1KMT2AALDH1A1 | |
| SCHEMBL13934764 | 0.86 | POLB (0.44) | POLBMCOLN3L3MBTL1KMT2AALDH1A1 | |
| SCHEMBL3831541 | 0.79 | MCOLN3 (0.49) | POLBMCOLN3L3MBTL1KMT2AALDH1A1 | |
| SCHEMBL3831546 | 0.79 | MCOLN3 (0.49) | POLBMCOLN3L3MBTL1KMT2AALDH1A1 | |
| SCHEMBL4531992 | 0.78 | MCOLN3 (0.48) | POLBMCOLN3L3MBTL1KMT2AALDH1A1 | |
| SCHEMBL4531996 | 0.78 | MCOLN3 (0.48) | POLBMCOLN3L3MBTL1KMT2AALDH1A1 | |
| SCHEMBL13934761 | 0.76 | MCOLN3 (0.46) | POLBMCOLN3L3MBTL1KMT2AALDH1A1 | |
| SCHEMBL4527209 | 0.75 | POLB (0.54) | POLBMCOLN3L3MBTL1KMT2AALDH1A1 | |
| SCHEMBL4539209 | 0.72 | POLB (0.46) | POLBMCOLN3L3MBTL1KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090054392-A1 | NAPHTHYLPYRIMIDINE, NAPHTHYLPYRAZINE AND NAPHTHYLPYRIDAZINE ANALOGS AND THEIR USE AS AGONISTS OF THE WNT-BETA-CATENIN CELLULAR MESSAGING SYSTEM | WYETH (US) | 2009-02-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090054392-A1 | NAPHTHYLPYRIMIDINE, NAPHTHYLPYRAZINE AND NAPHTHYLPYRIDAZINE ANALOGS AND THEIR USE AS AGONISTS OF THE WNT-BETA-CATENIN CELLULAR MESSAGING SYSTEM | WNT1, CTNNB1, WNT3A | POLB 2373/4885MCOLN3 2688/4885L3MBTL1 3907/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.